Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
The relationship between a primary and excess insurance carrier within the context of a catastrophic medical malpractice litigation is fraught with possible pitfalls.
Columns & Departments
A look at a recent case in which the DOJ leveraged FIRREA.
Given the DOJ's aggressive use of asset forfeitures, including higher-value forfeitures, counsel should be prepared to seek <i>Monsanto</i> hearings.
Features
While there have been high-profile setbacks to be sure, there is little reason to expect FCPA enforcement actions ' characterized by some as a tool in the war on terror ' to decline.
Features
The Department of Justice (DOJ) and Securities Exchange Commission's (SEC) Guide to the U.S. Foreign Corrupt Practices Act (FCPA) demonstrates, if there were any doubt, the importance of timely and effective FCPA remediation.
The Food and Drug Administration (FDA) provides some protection to drug companies regarding adverse event reports by allowing a disclaimer statement about liability. However, this is not a blanket defense against other potential liability exposure.
Features
If district courts must rule conclusively whether expert testimony will be admissible at trial before making a Rule 23 determination, parties may have to engage in considerable discovery before class certifications can be made.
Features
Whether a case is litigated in federal court rather than state court can have a huge impact on both litigation costs and the end result. Some proposals for federal jurisdiction reform.
An in-depth look at how forensic psychologists conduct child custody evaluations
